RPE65 and eye disorder: VN is the first therapeutic compound that achieved the approval of both the FDA and the EMA for an in vivo gene therapy of an eye disease and is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal disease with sufficient remaining viable retinal cells [3,4,5].